Matrine inhibits the proliferation of neuroblastoma LA-N-5 cell and MYCN mRNA expression.
- Author:
Chen FENG
1
;
Suo-Qin TANG
;
Jian-Wen WANG
;
Hui LONG
;
Guang YANG
Author Information
- Publication Type:Journal Article
- MeSH: Alkaloids; pharmacology; Cell Line, Tumor; Cell Proliferation; drug effects; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; drug therapy; metabolism; pathology; Nuclear Proteins; genetics; Oncogene Proteins; genetics; Quinolizines; pharmacology; RNA, Messenger; analysis
- From: Chinese Journal of Contemporary Pediatrics 2008;10(2):225-227
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVENeuroblastoma is the most common malignant solid tumor in children under 4 years. Amplification of MYCN oncogene is associated with advanced-stage disease, rapid tumor progression, resistance to treatment, and poor outcome. Matirne has the anti-tumor activity. This study was designed to investigate the effects of matrine on LA-N-5 cell line proliferation and MYCN gene mRNA expression.
METHODSNeuroblastoma LA-N-5 cells were treated by 0.25, 0.50, 0.75 or 1.00 mg/mL matrine. MTT was used to measure the levels of the proliferation of LA-N-5 cells cultured with different concentrations of matrine. MYCN gene mRNA expression in LA-N-5 cells was measured using real time RT-PCR with SYBR GREEN I fluorescence.
RESULTSThe proliferation of LA-N-5 cells was obviously inhibited by matrine in a dose- and time- dependent manner. Matrine of 1.00 mg/mL treatment for 72 hrs produced a best effect, with an inhibitory rate of LA-N-5 cell proliferation of 36.3% and an inhibitory rate of MYCN gene mRNA expression of 44.6%.
CONCLUSIONSMatrine may inhibit the growth of neuroblastoma cells and down-regulate MYCN mRNA expression. It may be promising as a new drug for treatment of neuroblastoma.
